文献速递呼吸道感染呼吸危重症与机械通气

清醒俯卧位用于COVID-19急性低氧性呼吸衰竭:随机对照跨国meta试验

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial.
PubMed 文献 · Lancet Respir Med · 2021-08-20

该研究为六项随机对照开放标签优效性试验的前瞻性协作meta试验,纳入1126例因COVID-19急性低氧性呼吸衰竭需高流量鼻导管支持的成人患者,随机分为清醒俯卧位组或标准护理组。结论认为清醒俯卧位减少治疗失败和插管需求且无伤害信号。

要点

  • 预设不良事件发生率低且两组相似,支持常规使用清醒俯卧位。

核心结论

  • 对COVID-19所致低氧性呼吸衰竭且需高流量鼻导管支持的患者,清醒俯卧位可减少治疗失败率和插管需求,且未观察到伤害信号。
  • 结果支持对此类患者常规实施清醒俯卧位。

研究设计与样本

  • 前瞻性、预先设定并定义的协作meta试验,整合六项随机对照开放标签优效性试验。
  • 纳入加拿大、法国、爱尔兰、墨西哥、美国、西班牙六国医院的成人患者,需高流量鼻导管支持。
  • 共纳入1126例患者,随机分为清醒俯卧位组(n=567)或标准护理组(n=559);1121例纳入意向性治疗分析(排除5例退出者)。
  • 主要复合结局为入组28天内插管或死亡的治疗失败比例。
  • 患者或照护提供者未对分配治疗设盲。

主要发现

  • 预设不良事件发生率低,两组相似。

关键数值与推荐

  • 主要复合结局治疗失败定义为入组28天内插管或死亡的比例。
  • 推荐对需要高流量鼻导管支持的COVID-19患者常规实施清醒俯卧位。

临床怎么用

  • 对COVID-19急性低氧性呼吸衰竭需高流量鼻导管支持的患者,可常规考虑清醒俯卧位以降低插管和死亡复合风险。
  • 实施时需关注预设不良事件,但本研究中发生率低且与标准护理相似。

局限性

  • 开放标签设计,患者或照护提供者未对分配治疗设盲。
  • 死亡率风险比95%CI包含1,未显示显著降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Awake prone positioning has been reported to improve oxygenation for patients with COVID-19 in retrospective and observational studies, but whether it improves patient-centred outcomes is unknown. We aimed to evaluate the efficacy of awake prone positioning to prevent intubation or death in patients with severe COVID-19 in a large-scale randomised trial. METHODS: In this prospective, a priori set up and defined, collaborative meta-trial of six randomised controlled open-label superiority trials, adults who required respiratory support with high-flow nasal cannula for acute hypoxaemic respiratory failure due to COVID-19 were randomly assigned to awake prone positioning or standard care. Hospitals from six countries were involved: Canada, France, Ireland, Mexico, USA, Spain. Patients or their care providers were not masked to allocated treatment. The primary composite outcome was treatment failure, defined as the proportion of patients intubated or dying within 28 days of enrolment. The six trials are registered with ClinicalTrials.gov, NCT04325906, NCT04347941, NCT04358939, NCT04395144, NCT04391140, and NCT04477655. FINDINGS: Between April 2, 2020 and Jan 26, 2021, 1126 patients were enrolled and randomly assigned to awake prone positioning (n=567) or standard care (n=559). 1121 patients (excluding five who withdrew from the study) were included in the intention-to-treat analysis. Treatment failure occurred in 223 (40%) of 564 patients assigned to awake prone positioning and in 257 (46%) of 557 patients assigned to standard care (relative risk 0·86 [95% CI 0·75-0·98]). The hazard ratio (HR) for intubation was 0·75 (0·62-0·91), and the HR for mortality was 0·87 (0·68-1·11) with awake prone positioning compared with standard care within 28 days of enrolment. The incidence of prespecified adverse events was low and similar in both groups. INTERPRETATION: Awake prone positioning of patients with hypoxaemic respiratory failure due to COVID-19 reduces the incidence of treatment failure and the need for intubation without any signal of harm. These results support routine awake prone positioning of patients with COVID-19 who require support with high-flow nasal cannula. FUNDING: Open AI inc, Rice Foundation, Projet Hospitalier de Recherche Clinique Interrégional, Appel d'Offre 2020, Groupement Interrégional de Recherche Clinique et d'Innovation Grand Ouest, Association pour la Promotion à Tours de la Réanimation Médicale, Fond de dotation du CHRU de Tours, Fisher & Paykel Healthcare Ltd.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Ehrmann S, Li J, Ibarra-Estrada M, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021. PMID: 34425070. doi:10.1016/S2213-2600(21)00356-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。